EPPTB

Source: Wikipedia, the free encyclopedia.
EPPTB
Identifiers
  • N-(3-ethoxyphenyl)-4-pyrrolidin-1-yl-3-trifluoromethylbenzamide
JSmol)
  • CCOc2cc(ccc2)NC(=O)c(cc1C(F)(F)F)ccc1N3CCCC3

  • CCOc1cccc(c1)NC(=O)c2ccc(c(c2)C(F)(F)F)N3CCCC3
  • InChI=1S/C20H21F3N2O2/c1-2-27-16-7-5-6-15(13-16)24-19(26)14-8-9-18(25-10-3-4-11-25)17(12-14)20(21,22)23/h5-9,12-13H,2-4,10-11H2,1H3,(H,24,26)
  • Key:KLFVWQCQUXXLOU-UHFFFAOYSA-N

EPPTB (RO-5212773) is a drug developed by

Hoffmann-La Roche which acts as a potent and selective inverse agonist of trace amine-associated receptor 1 (TAAR1), with no significant activity at other targets. EPPTB is one of the first selective antagonists developed for TAAR1, and has been used to demonstrate an important role for TAAR1 in regulation of dopaminergic signalling in the limbic system.[1] Although EPPTB has high affinity for the mouse TAAR1, it has much lower affinity for rat and human TAAR1, which limits its use in research.[2] While the human and mouse forms of TAAR1 have similar functions and bind similar ligands, the actual binding affinities of individual ligands often vary significantly between the two versions of the receptor.[3]

See also

References

This page is based on the copyrighted Wikipedia article: EPPTB. Articles is available under the CC BY-SA 3.0 license; additional terms may apply.Privacy Policy